Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Paul Burstow

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

Eisai submits new drug application for subcutaneous Leqembi in Japan

LEQEMBI is a treatment for early Alzheimer’s disease

- PMLiVE

Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug Leqembi granted EC approval

The neurodegenerative disorder currently affects an estimated 6.9 million people in Europe

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

The neurodegenerative disorder affects an estimated 6.9 million people in Europe

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

The health technology assessment agency outlined that the drug's benefits are “too small” to justify its costs

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links